News coverage about Natus Medical (NASDAQ:BABY) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Natus Medical earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.9260093535533 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Several analysts recently issued reports on the stock. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $48.00.

Natus Medical (NASDAQ BABY) traded up 1.01% during trading on Thursday, reaching $40.10. 414,350 shares of the company’s stock were exchanged. The stock has a market cap of $1.30 billion, a PE ratio of 69.50 and a beta of 0.95. The firm has a 50 day moving average of $34.72 and a 200-day moving average of $35.99. Natus Medical has a 12 month low of $31.65 and a 12 month high of $44.38.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. During the same period last year, the company earned $0.39 earnings per share. The company’s revenue was up 27.3% on a year-over-year basis. On average, equities research analysts anticipate that Natus Medical will post $1.70 earnings per share for the current fiscal year.

In other news, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the transaction, the director now directly owns 50,850 shares in the company, valued at $1,788,394.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William M. Moore sold 3,000 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $34.10, for a total value of $102,300.00. Following the transaction, the director now owns 30,410 shares of the company’s stock, valued at $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

WARNING: “Natus Medical (BABY) Receives News Sentiment Rating of 0.10” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/05/natus-medical-baby-receives-news-sentiment-rating-of-0-10.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.